scispace - formally typeset
Journal ArticleDOI

What is the true solubility advantage for amorphous pharmaceuticals

Bruno C. Hancock, +1 more
- 01 Apr 2000 - 
- Vol. 17, Iss: 4, pp 397-404
Reads0
Chats0
TLDR
Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations.
Abstract
Purpose To evaluate the magnitude of the solubility advantage foramorphous pharmaceutical materials when compared to their crystallinecounterpartsMethods The thermal properties of several drugs in their amorphousand crystalline states were determined using differential scanningcalorimetry From these properties the solubility advantage for theamorphous form was predicted as a function of temperature using a simplethermodynamic analysis These predictions were compared to theresults of experimental measurements of the aqueous solubilities of theamorphous and crystalline forms of the drugs at several temperaturesResults By treating each amorphous drug as either an equilibriumsupercooled liquid or a pseudo-equilibrium glass, the solubilityadvantage compared to the most stable crystalline form was predicted to bebetween 10 and 1600 fold The measured solubility advantage wasusually considerably less than this, and for one compound studied indetail its temperature dependence was also less than predicted It wascalculated that even for partially amorphous materials the apparentsolubility enhancement (theoretical or measured) is likely to influencein-vitro and in-vivo dissolution behaviorConclusions Amorphous pharmaceuticals are markedly more solublethan their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations This appears to be the result of difficulties indetermining the solubility of amorphous materials under trueequilibrium conditions Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage foramorphous pharmaceuticals, which directly reflects the driving forcefor their initial dissolution

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Formation of hydrophobic drug nanoparticles via ambient solvent evaporation facilitated by branched diblock copolymers

TL;DR: UV-vis spectroscopy has been used to determine the yield of drug suspended in aqueous media while cryo-TEM, dynamic light scattering (DLS) and powder x-ray diffraction (PXRD) are used to characterize the drug nanoparticles prepared.

Hydroxyapatite-based materials for smart antitumor drug delivery systems, endocytic pathways and endosomal trafficking

TL;DR: The main goal of this Thesis is to design an effective MDR reversing nanoparticulate drug delivery system consists of a HAp polymeric matrix from which the drug is released intracellularly.
Journal ArticleDOI

Exploring the Potential of Mesoporous Silica as a Carrier for Puerarin: Characterization, Physical Stability, and In Vivo Pharmacokinetics

TL;DR: AP has a high pore volume, large specific surface area, excellent flowability, and hydrophilic properties, making it capable of improving the dissolution and bioavailability of poorly water-soluble drugs.
Journal ArticleDOI

Sucrose/Glucose Molecular Alloys by Cryomilling

TL;DR: Differential scanning calorimetry, X-ray powder diffraction and solution proton nuclear magnetic resonance showed that cryomilling drives a direct transformation from a two-phase mixture of crystalline sucrose and glucose, to a single-phase amorphous sucrose/glucose molecular alloy.

Silice a mesoporosità ordinata come carrier di curcumina = Ordered mesoporous silica as carrier for curcumin

TL;DR: In this article, the curcumina has been used for drug delivery in a silice a mesoporosita ordinata (SBA-15) in the USA.
References
More filters
Journal ArticleDOI

Characteristics and Significance of the Amorphous State in Pharmaceutical Systems

TL;DR: The amorphous state is critical in determining the solid-state physical and chemical properties of many pharmaceutical dosage forms and some of the most common methods that can be used to measure them are described.
Book

Polymorphism in Pharmaceutical Solids

TL;DR: Brittain et al. as mentioned in this paper applied the phase rule to the characterisation of polymorphic and solvatomorphic systems, and proposed a computational method to predict polymorphism.
Journal ArticleDOI

Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations

TL;DR: It is hoped that this review will lead to a more direct approach to the characterization of pharmaceuticalsolids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.
Journal ArticleDOI

Crystallization of Indomethacin from the Amorphous State below and above Its Glass Transition Temperature

TL;DR: It was shown that in both samples significant crystallization to the most stable polymorphic form occurred over several days when stored below Tg, and in some cases this process was preceded by the relaxation of one amorphous form to the other.
Journal ArticleDOI

Characterization of the time scales of molecular motion in pharmaceutically important glasses

TL;DR: In this paper, the authors characterized the molecular mobility of selected amorphous systems (i.e., indomethacin, sorbitol, sucrose, and trehalose) below Tg using a combined experimental and theoretical approach.
Related Papers (5)